✦ LIBER ✦

Frequent occurrence of metastatic disease in patients with renal cell carcinoma and intrahepatic or supradiaphragmatic intracaval extension treated with surgery: an outcome analysis

✍ Scribed by Thomas J. Polascik; Alan W. Partin; Charles R. Pound; Fray F. Marshall

Book ID: 119487521
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 113 KB
Volume: 52
Category: Article
ISSN: 0090-4295
DOI: 10.1016/s0090-4295(98)00367-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Disease Outcome in Patients With Low Sta

Disease Outcome in Patients With Low Stage Renal Cell Carcinoma Treated With Nephron Sparing or Radical Surgery

✍ Lerner, Seth E.; Hawkins, Craig A.; Blute, Michael L.; Grabner, Andreas; Wollan, 📂 Article 📅 1996 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 773 KB

Disease outcome in patients with low sta

Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery

✍ Lerner, Seth E.; Hawkins, Craig A.; Blute, Michael L.; Grabner, Andreas; Wollan, 📂 Article 📅 2002 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 802 KB

Patterns of disease progression in metas

Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon : Impact of therapy on recurrence patterns and outcome measures

✍ Elizabeth R. Plimack; Nizar Tannir; E Lin; B. Nebiyou Bekele; Eric Jonasch 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 234 KB 👁 1 views

Efficacy and Safety of Everolimus in Eld

Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial

✍ Camillo Porta; Emiliano Calvo; Miguel A. Climent; Ulka Vaishampayan; Susanne Osa 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 424 KB

7131 POSTER Optimizing the Sequencial Tr

7131 POSTER Optimizing the Sequencial Treatment of Metastatic Renal Cell Carcinoma (MRCC) – a Retrospective, Multicenter, Analysis of 40 Patients Treated With Either Sorafenib, an mTOR Inhibitor (mTORI) and Sunitinib, or Sunitinib, an mTORI and Sorafenib

✍ Porta, C.; Paglino, C.; Procopio, G.; Sabbatini, R.; Bellmunt, J.; Schmidinger, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

A cost-effectiveness analysis of sunitin

A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System

✍ L. Paz-Ares; J. G. Del Muro; E. Grande; S. Díaz 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB